Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2023-12-15
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical and Molecular Evaluation of Childern With Familial Meditterranean Fever and Their Siblings
NCT05488561
Colchicine Levels in the Serum of FMF (Familial Mediterranean Fever) Patients
NCT03210610
Health-related Quality of Life, Electrocardiographic and Holter Findings in Children With Familial Mediterranean Fever
NCT07128225
Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation
NCT02175589
Mobile App-Based Infection Monitoring in Familial Mediterranean Fever
NCT07212764
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To mention the most common genetic variants reported in FMF patients in Upper Egypt, and to correlate the genetic variant with the risk to develop atherosclerosis.
* To assess the growth parameters in patients with FMF and compare it with the control group.
* To estimate the differences in Complete blood count (CBC) parameters, lipid profile, CIT in patients with FMF and control group.
* To search for subclinical atherosclerosis in patients with FMF based on their lipid profile and CIT.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CROSSOVER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
carotid intima thickness measurment
CIT will be assessed using ultrasound evaluation by measuring the intima-media thickness of carotid arteries (IMT). This non-invasive method is used to detect subclinical atherosclerosis and it can be used in a multitude of patients including children. It will be carried out on the two study groups (FMF patients and the control group) and the results will be compared. It will be conducted in Assiut University Neurosonology Unit, at the Department of Neurology.
ultrasound on carotid
CIT will be assessed using ultrasound evaluation by measuring the intima-media thickness of carotid arteries (IMT). This non-invasive method is used to detect subclinical atherosclerosis and it can be used in a multitude of patients including children\[11\]. It will be carried out on the two study groups (FMF patients and the control group) and the results will be compared. It will be conducted in Assiut University Neurosonology Unit, at the Department of Neurology.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ultrasound on carotid
CIT will be assessed using ultrasound evaluation by measuring the intima-media thickness of carotid arteries (IMT). This non-invasive method is used to detect subclinical atherosclerosis and it can be used in a multitude of patients including children\[11\]. It will be carried out on the two study groups (FMF patients and the control group) and the results will be compared. It will be conducted in Assiut University Neurosonology Unit, at the Department of Neurology.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Both sexes.
3. Diagnosed as familial Mediterranean fever according to Tel Hashomer criteria. \[10\]
Exclusion Criteria
2. Patients with pre-existing illness as chronic lung, liver or renal diseases.
3. Patients with diabetes mellitus, atherosclerotic vascular disease.
4. Patients with malignancy
1 Year
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ali AbdElhaleem Hussein
Doctor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Naglaa mohamed samy, lecturer
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMF and atheroscelerosis
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.